Grufity logoGrufity logo
StocksFundsSearch FilingsAPI

Veracyte Inc Stock Research

VCYT

22.47USD-0.13(-0.58%)Market Closed
Watchlist

Market Summary

USD22.47-0.13
Market Closed
-0.58%

VCYT Alerts

  • Losses in recent quarter

VCYT Stock Price

VCYT RSI Chart

VCYT Valuation

Market Cap

1.6B

Price/Earnings (Trailing)

-56.17

Price/Sales (Trailing)

4.97

EV/EBITDA

-633.47

Price/Free Cashflow

70.9

VCYT Price/Sales (Trailing)

VCYT Profitability

EBT Margin

-9.66%

Return on Equity

-2.79%

Return on Assets

-2.61%

Free Cashflow Yield

1.41%

VCYT Fundamentals

VCYT Revenue

Revenue (TTM)

328.6M

Revenue Y/Y

23.96%

Revenue Q/Q

9.58%

VCYT Earnings

Earnings (TTM)

-29.1M

Earnings Y/Y

11.85%

Earnings Q/Q

-3.84%

Price Action

52 Week Range

14.9231.09
(Low)(High)

Last 7 days

-10.3%

Last 30 days

-14.4%

Last 90 days

-12.0%

Trailing 12 Months

34.5%

VCYT Financial Health

Current Ratio

4.49

VCYT Investor Care

Shares Dilution (1Y)

1.63%

Diluted EPS (TTM)

-0.4

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs
Net sales

Latest Insider Trading transactions for VCYT

Filter Transactions
Datesorted ascendingNameBuy/Sell$ ValueAvg. Price# SharesTitle
2023-09-02
Wygant Jonathan
sold (taxes)
-33,294
26.7
-1,247
vp, chief accounting officer
2023-09-02
Stapley Marc
sold (taxes)
-85,546
26.7
-3,204
chief executive officer
2023-09-02
Chambers Rebecca
sold (taxes)
-97,508
26.7
-3,652
chief financial officer
2023-09-02
McGuire Annie
sold (taxes)
-46,164
26.7
-1,729
svp, general counsel
2023-09-02
Leite John
sold (taxes)
-59,327
26.7
-2,222
chief commercial officer-clia
2023-07-19
JONES EVAN/ FA
sold
-93,232
30.1723
-3,090
-
2023-07-19
JONES EVAN/ FA
sold
-25,257
30.1398
-838
-
2023-07-18
JONES EVAN/ FA
sold
-224,616
30.1863
-7,441
-
2023-07-18
BISHOP JOHN L
acquired
63,700
6.37
10,000
-
2023-07-18
JONES EVAN/ FA
sold
-70,089
30.1591
-2,324
-

1–10 of 50

Which funds bought or sold VCYT recently?

View All Details
Datesorted ascendingFund NameType% Chg$ Change$ Held% Portfolio
2023-09-20
BARCLAYS PLC
added
21.63
1,265,000
4,514,000
-%
2023-09-12
Farther Finance Advisors, LLC
unchanged
-
47.00
382
-%
2023-08-29
EFG Asset Management (Americas) Corp.
reduced
-4.17
31,533
365,163
0.09%
2023-08-25
Yarbrough Capital, LLC
unchanged
-
31,053
249,504
0.01%
2023-08-22
COMERICA BANK
new
-
34,000
34,000
-%
2023-08-21
CALIFORNIA STATE TEACHERS RETIREMENT SYSTEM
reduced
-2.22
233,622
2,233,820
-%
2023-08-21
VitalStone Financial, LLC
unchanged
-
-1,000
-
-%
2023-08-21
OSAIC HOLDINGS, INC.
added
0.98
59,534
446,865
-%
2023-08-21
TEACHERS RETIREMENT SYSTEM OF THE STATE OF KENTUCKY
added
13.97
227,000
979,000
0.01%
2023-08-18
Legato Capital Management LLC
added
36.37
422,262
1,179,590
0.16%

1–10 of 48

Latest Funds Activity

Are funds buying VCYT calls or puts?
Calls
Puts
No. of funds holding Calls - Puts
Net Call Options
No. of funds that own VCYT
No. of Funds

Schedule 13G FIlings of Veracyte

Date FiledName of FilerPercent of ClassNo. of SharesForm Type
Jun 09, 2023
wellington management group llp
10.01%
7,248,889
SC 13G/A
Feb 09, 2023
william blair investment management, llc
0.8%
558,384
SC 13G/A
Feb 09, 2023
vanguard group inc
9.55%
6,852,657
SC 13G/A
Feb 06, 2023
state street corp
5.80%
4,159,331
SC 13G
Feb 06, 2023
wellington management group llp
9.25%
6,636,543
SC 13G/A
Jan 25, 2023
blackrock inc.
9.1%
6,534,569
SC 13G/A
Feb 14, 2022
nikko asset management americas, inc.
4.39%
3,121,103
SC 13G/A
Feb 10, 2022
invesco ltd.
5.8%
4,114,031
SC 13G/A
Feb 09, 2022
ark investment management llc
11.57%
8,222,281
SC 13G/A
Feb 04, 2022
artisan partners limited partnership
7.0%
4,956,409
SC 13G/A

Recent SEC filings of Veracyte

View All Filings
Date Filed Form Type Document
Sep 06, 2023
3
Insider Trading
Sep 06, 2023
4
Insider Trading
Sep 06, 2023
4
Insider Trading
Sep 06, 2023
4
Insider Trading
Sep 06, 2023
4
Insider Trading
Sep 06, 2023
4
Insider Trading
Aug 09, 2023
10-Q
Quarterly Report
Aug 08, 2023
8-K
Current Report
Jul 24, 2023
4
Insider Trading
Jul 19, 2023
144
Notice of Insider Sale Intent

Peers (Alternatives to Veracyte)

View All Peers In Detail
NameMkt Capsorted ascendingRevenuePrice %, 1MReturns, 1YP/EP/SRev 1-YrInc 1-Yr
LARGE-CAP
269.9B
56.0B
3.85% 7.89%
31.08
4.82
-2.31% -31.27%
90.1B
9.5B
-0.31% 22.07%
26.78
9.48
13.83% 5.33%
88.3B
12.7B
-1.90% 19.84%
20.53
6.97
-10.94% -24.40%
13.0B
3.5B
-10.13% -13.81%
35.41
3.69
5.81% -61.22%
MID-CAP
5.2B
931.0M
-16.86% -0.76%
-10.21
5.61
28.69% 11.08%
2.9B
256.2M
-4.82% -13.52%
-16.11
11.39
2.51% -17.66%
SMALL-CAP
1.6B
328.6M
-14.37% 34.47%
-56.17
4.97
22.46% 40.27%
442.5M
167.5M
-10.46% -33.92%
-4.98
2.64
52.01% -99.69%
413.7M
309.3M
-12.66% -52.30%
-4.93
1.34
-1.76% -21.01%
317.8M
457.3M
-9.02% -24.14%
31.63
0.69
-0.61% -85.93%
220.2M
-
-2.83% 14.20%
-4.49
-
- -59.74%
176.8M
493.9M
-33.66% -73.83%
-0.22
0.36
-1.39% 74.28%
1.6M
2.8M
29.38% -44.90%
-0.04
0.57
-31.25% -41.90%

Veracyte News

Best Stocks
Title Groundbreaking Research on Thyroid Nodules and Tumors ....
Best Stocks,
2 days ago
Business Wire
Simply Wall St

Returns for VCYT

Cumulative Returns on VCYT

17.2%


7-Year Cumulative Returns

17.5%


5-Year Cumulative Returns

-10.7%


3-Year Cumulative Returns

Risks for VCYT

What is the probability of a big loss on VCYT?

100%


Probability that Veracyte stock will be more than 20% underwater in next one year

67.7%


Probability that Veracyte stock will be more than 30% underwater in next one year.

45.4%


Probability that Veracyte stock will be more than 40% underwater in next one year.
*Calculated based on probability distribution of losses observed in actual data in the last 5 years.

How does VCYT drawdown profile look like?

Y-axis is the maximum loss one would have experienced if Veracyte was unfortunately bought at previous high price.

Drawdowns

Financials for Veracyte

Income Statement (Last 12 Months)
Income Statement (Last 12 Months)
Description(%) Q/Q2023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q12018Q42018Q32018Q2
Revenue5.6%328,633,000311,175,000296,536,000283,575,000268,353,000250,594,000219,514,000186,714,000157,465,000123,064,000117,483,000112,677,000112,529,000121,961,000120,368,000116,388,000108,881,000101,496,00092,008,00085,854,00079,907,000
Cost Of Revenue---------------36,077,00035,108,00034,255,00033,724,00033,078,00032,143,00031,051,000
Costs and Expenses4.3%362,282,000347,506,000337,617,000331,569,000323,348,000302,330,000301,417,000264,356,000222,492,000191,668,000152,872,000148,191,000145,740,000147,221,000135,495,000126,375,000121,409,000116,841,000114,241,000111,074,000107,191,000
Operating Expenses-------------------114,241,000--
  S&GA Expenses1.8%101,691,00099,936,00097,560,00095,645,00091,637,00087,298,00079,840,00070,777,00060,062,00051,101,00052,389,00053,423,00055,556,00058,798,00053,691,00049,574,00046,567,00042,247,00041,313,00040,292,00038,096,000
  R&D Expenses7.2%47,370,00044,206,00040,603,00039,568,00036,801,00033,673,00029,843,00024,177,00020,213,00018,133,00017,204,00017,061,00016,662,00015,823,00014,851,00013,533,00013,309,00014,580,00014,820,00014,897,00014,524,000
EBITDA100.0%--4,003,000-10,490,000-18,527,000-25,423,000-26,846,000-61,998,000-63,099,000-55,731,000-60,107,000-26,736,000-28,364,000-39,046,000-41,291,000-7,806,000------
EBITDA Margin100.0%--0.01-0.04-0.07-0.09-0.11-0.28-0.34-0.35-0.49-0.23-0.25-0.35-0.34-0.06------
Interest Expenses---9,000--63,0009,00073,000128,000130,00013,000-89,000-86,00084,000332,0001,132,0001,572,0001,818,0001,963,0003,945,0004,262,000
Earnings Before Taxes4.6%-28,684,000-30,054,000-36,427,000-44,254,000-50,858,000-50,401,000-81,600,000-78,376,000-67,021,000-68,856,000-34,909,000-35,820,000-45,482,000-46,864,000-12,599,000------
EBT Margin100.0%--0.10-0.12-0.16-0.19-0.20-0.37-0.42-0.43-0.56-0.30-0.32-0.40-0.38-0.10------
Net Income3.7%-29,060,000-30,190,000-36,560,000-43,244,000-48,650,000-48,156,000-75,563,000-73,079,000-63,074,000-65,061,000-34,909,000-34,323,000-30,929,000-22,398,000-12,599,000-8,246,000-11,985,000-15,739,000-22,999,000-28,333,000-30,913,000
Net Income Margin100.0%--0.10-0.12-0.15-0.18-0.19-0.34-0.39-0.40-0.53-0.30-0.30-0.27-0.18-0.10------
Free Cashflow-100.0%-7,146,000-1,014,000-1,281,000-9,798,000-6,565,000-36,997,000-43,229,000-38,907,000-48,339,000-12,548,000-13,231,000-16,136,000-10,178,000-5,988,000------
Balance Sheet
(In Millions)
Balance Sheet
(In Millions)
(*) denotes actual numbers (not divided by Millions)
Description(%) Q/Q2023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q12018Q42018Q32018Q2
Assets0.3%1,1611,1571,1561,1261,1441,1741,1881,1861,0271,02545745425726727526025212412111965.00
  Current Assets3.2%25925224923923523824322937136237637017318118822822091.0097.0095.0042.00
    Cash Equivalents7.4%19117815417015416417416532832534934614815416019619368.0079.0078.0024.00
  Inventory-13.0%12.0013.0014.0014.0015.0012.0011.0010.007.006.005.004.007.006.007.007.005.004.003.003.003.00
  Net PPE---------12.0011.009.009.009.009.009.008.008.008.009.009.009.00
  Goodwill-0.1%6997006966776907047087144724753.003.003.003.003.001.001.001.001.001.001.00
Liabilities3.3%78.0076.0081.0078.0080.0088.0091.0079.0056.0051.0036.0031.0031.0037.0036.0029.0028.0040.0041.0040.0040.00
  Current Liabilities3.9%58.0056.0063.0058.0059.0063.0064.0050.0036.0033.0017.0014.0013.0019.0017.0017.0015.0014.0013.0010.0010.00
    LT Debt, Current----1.001.001.001.00-----------1.00--
    LT Debt, Non Current--------1.001.001.001.001.001.001.001.001.001.0013.0024.0025.0025.00
Shareholder's Equity0.1%1,0831,0811,0751,0481,0641,0851,0971,10797197442142322623023923122484.0080.0079.0026.00
  Retained Earnings-2.1%-410-401-393-389-381-371-357-346-332-323-281-273-269-258-246-239-238-236-234-230-226
  Additional Paid-In Capital0.7%1,5211,5101,5001,4921,4831,4771,4691,4621,3041,298703696496489486470463320314310252
Shares Outstanding0.4%73.0072.0072.0072.0071.0071.0071.0070.0067.0063.0058.0055.0050.0050.0050.0049.0046.0041.0037.0039.0034.00
Cashflow (Last 12 Months)
(In Millions)
Cashflow (Last 12 Months)
(In Millions)
Description(%) Q/Q2023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q12018Q42018Q32018Q2
Cashflow From Operations119.7%31.0014.008.006.00-2.180.00-31.62-37.81-34.66-44.97-9.71-10.18-13.49-7.52-3.23-6.25-6.47-7.12-13.52-18.11-21.43
  Share Based Compensation15.8%33.0028.0027.0027.0027.0025.0023.0019.0015.0014.0013.0012.0012.0011.0010.008.007.007.006.006.006.00
Cashflow From Investing197.5%3.00-2.85-29.39-2.57-176-166-739-740-576-578-3.84-44.05-42.64-42.65-42.73-2.09-2.52-2.40-1.87-1.72-1.79
Cashflow From Financing14.8%4.003.003.004.005.007.0059659979379520420411.0013512712617850.0059.0056.000.00

VCYT Income Statement

2023-06-30
Condensed Consolidated Statements of Operations (Unaudited) - USD ($)
$ in Thousands
3 Months Ended6 Months Ended
Jun. 30, 2023
Jun. 30, 2022
Jun. 30, 2023
Jun. 30, 2022
Revenue:    
Total revenue$ 90,322$ 72,864$ 172,744$ 140,647
Operating expenses:    
Research and development12,5419,37725,31018,543
Selling and marketing25,75624,00151,88647,755
General and administrative25,04719,79847,51040,710
Intangible asset amortization5,3415,39110,67010,877
Total operating expenses98,37383,597191,293166,628
Loss from operations(8,051)(10,733)(18,549)(25,981)
Other income (loss), net(226)1,0862,1811,870
Loss before income taxes(8,277)(9,647)(16,368)(24,111)
Income tax expense (benefit)125(115)125(118)
Net loss$ (8,402)$ (9,532)$ (16,493)$ (23,993)
Net loss per common share, basic (in USD per share)$ (0.12)$ (0.13)$ (0.23)$ (0.34)
Net loss per common share, diluted (in USD per share)$ (0.12)$ (0.13)$ (0.23)$ (0.34)
Shares used to compute net loss per common share, basic (in shares)72,478,66271,476,96672,327,89771,354,002
Shares used to compute net loss per common share, diluted (in shares)72,478,66271,476,96672,327,89771,354,002
Testing revenue    
Revenue:    
Total revenue$ 81,749$ 59,718$ 154,145$ 115,698
Operating expenses:    
Cost of revenue23,33318,58442,98136,107
Product revenue    
Revenue:    
Total revenue4,0113,1087,9036,087
Operating expenses:    
Cost of revenue2,3151,6464,4773,221
Biopharmaceutical and other revenue    
Revenue:    
Total revenue4,56210,03810,69618,862
Operating expenses:    
Cost of revenue$ 4,040$ 4,800$ 8,459$ 9,415

VCYT Balance Sheet

2023-06-30
Condensed Consolidated Balance Sheets (unaudited) - USD ($)
Jun. 30, 2023
Dec. 31, 2022
Current assets:  
Cash and cash equivalents$ 191,142,000$ 154,247,000
Short-term investments024,605,000
Accounts receivable42,365,00044,021,000
Supplies and inventory11,572,00014,294,000
Prepaid expenses and other current assets14,401,00011,469,000
Total current assets259,480,000248,636,000
Property, plant and equipment, net18,510,00017,702,000
Right-of-use assets, operating leases12,455,00013,160,000
Intangible assets, net164,744,000174,866,000
Goodwill698,920,000695,891,000
Restricted cash889,000749,000
Other assets6,116,0005,418,000
Total assets1,161,114,0001,156,422,000
Current liabilities:  
Accounts payable12,895,00011,911,000
Accrued liabilities34,427,00037,774,000
Current portion of deferred revenue2,378,0002,613,000
Current portion of acquisition-related contingent consideration3,359,0006,060,000
Current portion of operating lease liabilities4,973,0004,070,000
Current portion of other liabilities119,000186,000
Total current liabilities58,151,00062,614,000
Deferred tax liabilities4,707,0004,531,000
Acquisition-related contingent consideration, net of current portion4,855,0002,498,000
Operating lease liabilities, net of current portion9,891,00010,648,000
Other liabilities792,000931,000
Total liabilities78,396,00081,222,000
Commitments and contingencies
Stockholders’ equity:  
Preferred stock, $0.001 par value; 5,000,000 shares authorized, no shares issued and outstanding as of June 30, 2023 and December 31, 202200
Common stock, $0.001 par value; 125,000,000 shares authorized, 72,643,156 and 71,959,454 shares issued and outstanding as of June 30, 2023 and December 31, 2022, respectively73,00072,000
Additional paid-in capital1,520,638,0001,500,191,000
Accumulated deficit(410,210,000)(393,717,000)
Accumulated other comprehensive loss(27,783,000)(31,346,000)
Total stockholders’ equity1,082,718,0001,075,200,000
Total liabilities and stockholders’ equity$ 1,161,114,000$ 1,156,422,000

About Veracyte